FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 17, 2020\n\n\n\nTORONTO, Jan. 17, 2020 /CNW/ - FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (\"FSD Pharma\" or the \"Company\") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company's Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET.\nThe Opening Bell Ringing Ceremony will be held at Nasdaq's MarketSite in New York City and will be webcast live beginning at 9:20 am ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony and live streaming will be available on Facebook at the following link: http://Facebook.com/Nasdaq.\n\"It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma's extended family and friends,\" said Raza Bokhari, MD, Executive Co-Chairman and CEO. \"The recent listing of our Class B Subordinate Voting Shares on Nasdaq has included us in a select group of 12 Canadian-domiciled cannabis companies that trade on a major U.S. exchange. I am, however, very hopeful that sooner rather than later we will  be placed in a league of our own as we continue to demonstrate that the primary thrust of our business is to focus on conducting clinical trials on synthetic compounds with anti-inflammatory properties that target the CB2 receptor of the endocannabinoid system of the human body.\"\nAbout FSD Pharma\nFSD Pharma is a specialty, biotech pharmaceutical R&D company focused on developing over time a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract and the musculosk...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B